Calendario›EDSA›SOC + 15mg
SOC + 15mg
Ensayo de Edesa Biotech, Inc. en COVID-19 · SDRA.
Más ensayos de: COVID-19.
- Fase
- Fase 2/3
- Estado
- Interrumpido
- Participantes
- 278
- Centros
- 20
- Fin del objetivo primario
- jul 2024
Título oficial en el registro (en inglés): A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, triple ciego. Comenzó en nov 2020.
Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Edesa has made the decision to terminate this study solely for business reasons. The study termination was not related to any safety concerns.».
De principio a fin
- Empieza el ensayo (nov 2020)
- Lectura de resultados jul 2024 (real)
- Cambia de estado: Suspendido → Interrumpido · visto el 1 oct 2026
- Hoy
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Lo que ha cambiado
Movimientos registrados desde que PivotalWire vigila este ensayo. Un retraso no se anuncia: se ve comparando, y esto es la comparación ya hecha.
| Visto | Qué se mueve | Cambio |
|---|---|---|
| 1 oct 2026 | Estado | Suspendido → Interrumpido |
Qué mide
Tasa de mortalidad en el dia 28 desde la administracion del IP. (28 dias)
Cómo lo describe el promotor
En el documentoEn inglés, del registroCOVID-19 patients who develop severe disease often develop acute respiratory distress syndrome (ARDS) as a result of a dysregulated immune response. This in turn stimulates a pro-inflammatory cascade ("cytokine storm") as well as emergency myelopoiesis. This proinflammatory cascade is activated when viral-mediated cell damage occurs in the lungs, resulting in the release of damage-signaling alarmin molecules such as S100A8/A9 (Calprotectin), HMGB1, Resistin, and oxidized phospholipids. These damage-associated molecular patterns (DAMPs) are recognized by the pattern recognition receptor Toll-Like Receptor 4 (TLR4) found on macrophages, dendritic cells and other innate immune cells and result in additional release of pro-inflammatory molecules. Several recent studies have shown that S100A8/A9 serum levels in hospitalized COVID-19 patients positively correlate with both neutrophil count and disease severity. Taken together the DAMP-TLR4 interaction forms a central axis in the innate immune system and is a key driver of the pathological inflammation observed in COVID-19. We hypothesis that targeting the initial step in the signalling pathways of these DAMPs in innate immunity offers the best hope for controlling the exaggerated host response to SARS-CoV-2 infection. EB05 has demonstrated safety in two clinical studies (>120 patients) and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans. Given, this extensive body of evidence we believe EB05 could ameliorate ARDS due to COVID-19, significantly reducing ventilation rates and mortality.
Más ensayos de EDSA
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| EB06 | Fase 2 | Reclutando pacientes | dic 2027 (prevista) |
| EB01 Cream Placebo | Fase 2 | Completado | sep 2022 (real) |
Todos los de EDSA, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT04401475), actualizada en oct 2026.